V8.0 版权所有© 2001-2026 渝B2-20050021-1
渝公网安备 50019002500403号违法和不良信息举报中心举报邮箱：jubao@cqvip.com
互联网出版许可证 新出网证(渝)字10号机构客服热线 023-67882612
- Expert consensus on the detection and clinical application of tumor mutational burden 认领 引用
- 1
- 作者 Zhenying Guo Chunwei Xu +168 位作者 Shirong Zhang Yue Hao Xiaotong Hu Ming Zhao Chan Xiang Yingshi Piao Pingli Sun Xueping Xiang Jing Zhao Huanwen Wu Weixing Li Jinpu Yu Jingping Yuan Shuangshuang Wang Cong Wang Yun Gu Bingjian Lv Liping Zhang Yueping Liu Xiaobin Cui Weizhong Gu Yining Li Wei Wang Wenjun Yang Weiguo Long Jingjing Xiang Hong Mou Biao Liu Huajuan Ruan Yubin Wang Yongjie Zhu Feng Wang Zhonghua Wang Xiaomin Feng Xing Liu Peng Li Min Deng Bin Lian Lili Mao Qian Wang Wenxian Wang Zhengbo Song Ziming Li Wenzhao Zhong Zhijie Wang Shengxiang Ren Wenfeng Fang Yongchang Zhang Jingjing Liu Xiuyu Cai Anwen Liu Wen Li Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Yu Zhang Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Peng Shen Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Rui Ge Enyong Dai Yu Han Jian Zhang Yinghua Ji Xianbin Liang Hongmei Zhang Xuelei Ma Xuewen Liu Yu Yao Peng Luo Weiwei Pan Fei Pang Fan Wu Dejian Gu Li Wang Liping Wang Youcai Zhu Li Lin Weiwen Li Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Yinbin Zhang Binbin Song Wenfeng Li Jianfei Fu Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Qing Ji Yuan Fang Qing Wei Zhen Wang Bin Wan Donglai Lv Xiaofeng Li Shengjie Yang Jing Kang Jiatao Zhang Chao Zhang Lin Shi Yina Wang Bihui Li Zhang Zhang Ke Wang Zhefeng Liu Nong Yang Lin Wu Xiaobing Chen Gu Jin Zhongwu Li Miao Li Guansong Wang Jiandong Wang Meiyu Fang Yong Fang Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Lu Si Yong Song Yuanzhi Lu Aijun Liu Yuchen Han 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第2期218-246,共29页
- As an emerging biomarker,tumor mutational burden(TMB)has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy.Currently,TMB is detected primarily by whole-exome sequencing o... As an emerging biomarker,tumor mutational burden(TMB)has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy.Currently,TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms.However,the lack of uniformity in detection methods,threshold settings,and reporting formats,as well as the significant differences in TMB values among different cancer types,have hindered the standardized application of this biomarker in clinical practice.This consensus focuses on the definition,standardization of detection,clinical significance,and limitations of TMB,and provides consensus recommendations for the clinical application of TMB in real-world practice in China.This consensus is aimed at helping clinicians and laboratory personnel understand the clinical significance and testing standards of TMB,promoting more accurate interpretation of test results,and improving patient care. 展开更多
- 关键词 Biomarkers tumor mutational burden tumor immunotherapy targeted panel sequencing whole-exome sequencing
- Human papillomavirus-associated diseases and cancers 认领 引用
- 2
- 作者 Lan Yang Jianbo Zhu +3 位作者 Xiaoyue Song Yan Qi Xiaobin Cui Feng Li 《Oncology and Translational Medicine》 CAS 2015年第3期109-114,共6页
- Human papillomaviruses(HPVs) have been detected in cervical cancer cells and skin papilloma cells, which have a variety of types, including low-risk and high-risk types. HPV genome replication requires the host cell&#... Human papillomaviruses(HPVs) have been detected in cervical cancer cells and skin papilloma cells, which have a variety of types, including low-risk and high-risk types. HPV genome replication requires the host cell's DNA synthesis machinery, and HPVs encode proteins that maintain differentiated epithelial cells in a replication-competent state. HPV types are tissue-specific and generally produce different types of lesions, either benign or malignant. This review examines different HPV types and their associated diseases and presents therapeutic options for the treatment of HPV-positive diseases. 展开更多
- 关键词 human papillomavirus （HPV） low-risk high-risk cancer
- 题名Expert consensus on the detection and clinical application of tumor mutational burden 认领 引用
- 1
- 作者 Zhenying Guo Chunwei Xu Shirong Zhang Yue Hao Xiaotong Hu Ming Zhao Chan Xiang Yingshi Piao Pingli Sun Xueping Xiang Jing Zhao Huanwen Wu Weixing Li Jinpu Yu Jingping Yuan Shuangshuang Wang Cong Wang Yun Gu Bingjian Lv Liping Zhang Yueping Liu Xiaobin Cui Weizhong Gu Yining Li Wei Wang Wenjun Yang Weiguo Long Jingjing Xiang Hong Mou Biao Liu Huajuan Ruan Yubin Wang Yongjie Zhu Feng Wang Zhonghua Wang Xiaomin Feng Xing Liu Peng Li Min Deng Bin Lian Lili Mao Qian Wang Wenxian Wang Zhengbo Song Ziming Li Wenzhao Zhong Zhijie Wang Shengxiang Ren Wenfeng Fang Yongchang Zhang Jingjing Liu Xiuyu Cai Anwen Liu Wen Li Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Yu Zhang Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Peng Shen Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Rui Ge Enyong Dai Yu Han Jian Zhang Yinghua Ji Xianbin Liang Hongmei Zhang Xuelei Ma Xuewen Liu Yu Yao Peng Luo Weiwei Pan Fei Pang Fan Wu Dejian Gu Li Wang Liping Wang Youcai Zhu Li Lin Weiwen Li Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Yinbin Zhang Binbin Song Wenfeng Li Jianfei Fu Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Qing Ji Yuan Fang Qing Wei Zhen Wang Bin Wan Donglai Lv Xiaofeng Li Shengjie Yang Jing Kang Jiatao Zhang Chao Zhang Lin Shi Yina Wang Bihui Li Zhang Zhang Ke Wang Zhefeng Liu Nong Yang Lin Wu Xiaobing Chen Gu Jin Zhongwu Li Miao Li Guansong Wang Jiandong Wang Meiyu Fang Yong Fang Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Lu Si Yong Song Yuanzhi Lu Aijun Liu Yuchen Han
- 机构 Cancer Center,Department of Pathology,Zhejiang Provincial People’s Hospital（Affiliated People’s Hospital）,Hangzhou Medical College Hangzhou Institute of Medicine（HIM）,Chinese Academy of Sciences Translational Medicine Research Center,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou First People’s Hospital,Cancer Center,Westlake University School of Medicine Department of Chemotherapy,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Department of Pathology,Sir Run Run Shaw Hospital,Zhejiang University Ningbo Clinical Pathology Diagnosis Center Department of Pathology,Shanghai Chest Hospital,Shanghai Jiao Tong University Department of Pathology,Beijing Tongren Hospital,Capital Medical University Department of Pathology,The Second Hospital of Jilin University Department of Pathology,The Second Affiliated Hospital,School of Medicine,Zhejiang University Department of Pathology,The First Affiliated Hospital,College of Medicine,Zhejiang University Department of Pathology,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College Laboratory Medicine Center,Zhejiang Center for Clinical Laboratory,Zhejiang Provincial People’s Hospital,Affiliated People’s Hospital,Hangzhou Medical College Department of Cancer Molecular Diagnostics Core,Tianjin Medical University Cancer Institute and Hospital Department of Pathology,Renmin Hospital of Wuhan University Department of Pathology,Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese Medicine Department of Pathology,The First Affiliated Hospital of Nanjing Medical University（Jiangsu Province Hospital） Department of Pathology,Women’s Hospital of Nanjing Medical University,Nanjing Women and Children’s Healthcare Hospital Department of Surgical Pathology Women’s Hospital,School of Medicine,Zhejiang University Department of Pathology,Shanghai Pudong Hospital,School of Medicine,Fudan University Department of Pathology,The Fourth Hospital of Hebei Medical University Department of Pathology,Nanjing Drum Tower Hospital,Nanjing University Department of Pathology,Children’s Hospital Zhejiang University School of Medicine Department of Pathology,Stomatology Hospital,School of Stomatology,Zhejiang University Department of Pathology,Tongde Hospital of Zhejiang Province Department of Pathology,Affiliated Hospital of Hangzhou Normal University Department of Pathology,The People’s Hospital of Leshan Department of Pathology,Affiliated Hangzhou First People’s Hospital,Westlake University School of Medicine Department of Pathology,Chun’an First People’s Hospital Department of Pathology,The Affiliated Suzhou Hospital,Nanjing Medical University Department of Pathology,The First People’s Hospital of Hangzhou Lin’an District,Affiliated Lin’an People’s Hospital,Hangzhou Medical College Department of Pathology,Tiantai County People’s Hospital Department of Pathology,First People’s Hospital of Aksu Department of Pathology,Xianju People’s Hospital,Zhejiang Southeast Campus of Zhejiang Provincial People’s Hospital,Affiliated Xianju’s Hospital,Hangzhou Medical College Department of Pathology,Dinghai Branch of Zhejiang Provincial People’s Hospital Department of Pathology,Shulan（Hangzhou）Hospital Department of Pathology,The First Affiliated Hospital of Wenzhou Medical University Department of Pathology,Zhejiang Provincial People’s Hospital（Fuyang Campus） Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Melanoma and Sarcoma,Peking University Cancer Hospital&Institute Department of Respiratory Medicine,Affiliated Hospital of Nanjing University of Chinese Medicine,Jiangsu Province Hospital of Chinese Medicine Department of Shanghai Lung Cancer Center,Shanghai Chest Hospital,Shanghai Jiao Tong University Guangdong Lung Cancer Institute,Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer,Guangdong Provincial People’s Hospital,Guangdong Academy of Medical Sciences,School of Medicine State Key Laboratory of Molecular Oncology,Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Department of Medical Oncology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Medical Oncology,Lung Cancer and Gastrointestinal Unit,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Thoracic Cancer,Jilin Cancer Hospital Department of VIP Inpatient,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine Department of Oncology,Second Affiliated Hospital of Nanchang University Key Laboratory of Respiratory Disease of Zhejiang Province,Department of Respiratory and Critical Care Medicine,Second Affiliated Hospital of Zhejiang University School of Medicine,Cancer Center,Zhejiang University Department of Respiratory Medicine,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Respiratory Medicine,Clinical Medical School of Yangzhou University,Subei People’s Hospital of Jiangsu Province Department of Medical Oncology,Fujian Medical University Cancer Hospital&Fujian Cancer Hospital Department of Oncology,Guizhou Provincial People’s Hospital Department of Internal Medicine,Cancer Center of PLA,Qinhuai Medical Area,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Integrative Oncology,Tianjin Medical University Cancer Institute and Hospital The Second Department of Thoracic Oncology,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University Department of Orthopedic Oncology Surgery,Beijing Ji shui tan Hospital,Peking University Department of Radiotherapy and Chemotherapy,Hwamei Hospital,University of Chinese Academy of Sciences Department of Pulmonary Medicine,Taizhou Hospital of Wenzhou Medical University Department of Respiratory Medicine,the 900th Hospital of the Joint Logistics Team（the Former Fuzhou General Hospital）,Fujian Medical University Department of Oncology,Nanfang Hospital,Southern Medical University Department of Oncology,Beijing Tiantan Hospital,Capital Medical University Department of Medical Oncology,Peking University International Hospital State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University Department of Thoracic Oncology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Department of Oncology,Shanghai East Hospital,School of Medicine,Tongji University Department of Oncology,The Second Affiliated Hospital of Medical College,Xi’an Jiaotong University Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology Department of Medical Oncology,The First Affiliated Hospital of Medicine,Xiamen University Department of Medical Oncology,Cancer Hospital of China Medical University Department of Medical Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology Department of Radiation Oncology,Fudan University Shanghai Cancer Center Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Radiation Oncology,Peking University Cancer Hospital&Institute State Key Laboratory of Cancer Biology,National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases,Fourth Military Medical University Department of Oncology,Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital Department of General Surgery,Huadong Hospital Affiliated to Fudan University Department of Oncology and Hematology,China-Japan Union Hospital of Jilin University Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital Department of Oncology,Zhujiang Hospital,Southern Medical University Department of Oncology,The First Affiliated Hospital of Xinxiang Medical University Department of Oncology,The Third People’s Hospital of Zhengzhou Department of Biotherapy,State Key Laboratory of Biotherapy,Cancer Center,West China Hospital,Sichuan University Department of Oncology,the Third Xiangya Hospital,Central South University Department of Medical Oncology,The First Affiliated Hospital of Xi’an Jiaotong University Department of Cell Biology,College of Medicine,Jiaxing University Department of Medical,Shanghai OrigiMed Co Department of Medical,Menarini Silicon Biosystems SpA Department of Medical,Geneplus-Beijing Department of Oncology,Baotou Cancer Hospital Department of Thoracic Disease Diagnosis and Treatment Center,Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University Department of Oncology,Lishui Municipal Central Hospital Department of Interventional Pulmonary Diseases,Anhui Chest Hospital Department of Medical Oncology,Qilu Hospital,Cheeloo College of Medicine,Shandong University Department of Medical Oncology,Shanghai Changzheng Hospital,Naval Medical University Department of Oncology,Shandong Provincial Third Hospital,Cheeloo College of Medicine,Shandong University Department of The Comprehensive Cancer Center,Affiliated Drum Tower Hospital,Medical School of Nanjing University Department of Pathology,Shanxi Academy of Medical Sciences,Shanxi Bethune Hospital Department of Oncology,The First Affiliated Hospital of Anhui Medical University Department of Interventional Oncology,The First Affiliated Hospital,Sun Yat-sen University Department of Respiratory Medicine,Huzhou Hospital,Zhejiang University School of Medicine Department of Medical Oncology,The Affiliated Hospital of Jiaxing University Department of Radiation Oncology,First Affiliated Hospital of Wenzhou Medical University Department of Medical Oncology,Affiliated Jinhua Hospital,Zhejiang University School of Medicine Senior Department of Oncology,The 5th Medical Center of PLA General Hospital Department of Pathology,Anhui Provincial Children’s Hospital Department of Radiation Oncology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Respiratory Medicine,The Affiliated Jiangning Hospital of Nanjing Medical University Department of Clinical Oncology,The 901 Hospital of Joint Logistics Support Force of People Liberation Army Department of Thoracic Surgery,Chuxiong Yi Autonomous Prefecture People’s Hospital Department of Respiratory Medicine,Zhongshan Hospital,Fudan University Department of Oncology,The First Affiliated Hospital,College of Medicine,Zhejiang University Department of Oncology,The Second Affiliated Hospital of Guilin Medical University International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education（MOE）,Guangzhou City Key Laboratory of Precision Chemical Drug Development,School of Pharmacy,Jinan University National Health Commission（NHC）Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,Jiangsu Institute of Nuclear Medicine Department of Radiopharmaceuticals,School of Pharmacy,Nanjing Medical University Department of Oncology,The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital Department of Bone and Soft-tissue Surgery,Chinese Academy of Sciences University Cancer Hospital（Zhejiang Cancer Hospital） Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）,Department of Pathology,Peking University Cancer Hospital&Institute Department of Oncology,The Cancer Hospital of Qinghai Province Institute of Respiratory Diseases,Xinqiao Hospital,Third Military Medical University Department of Pathology,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University Department of Thoracic Surgery,Affiliated Jinling Hospital,Medical School of Nanjing University Department of Oncology,Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province,Affiliated Hangzhou Cancer Hospital,Cancer Center,Westlake University School of Medicine Department of Breast Cancer and Urological Medical Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University Department of Clinical Pathology,The First Affiliated Hospital of Jinan University Senior Department of Pathology,the 7th Medical Center of PLA General Hospital
- 出处 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第2期218-246,共29页
- 基金 supported by grants from the National Natural Science Foundation of China(Grant No.82072577) from the International Medical Association(Grant No.IMA-F-2025-001).
- 摘要 As an emerging biomarker,tumor mutational burden(TMB)has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy.Currently,TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms.However,the lack of uniformity in detection methods,threshold settings,and reporting formats,as well as the significant differences in TMB values among different cancer types,have hindered the standardized application of this biomarker in clinical practice.This consensus focuses on the definition,standardization of detection,clinical significance,and limitations of TMB,and provides consensus recommendations for the clinical application of TMB in real-world practice in China.This consensus is aimed at helping clinicians and laboratory personnel understand the clinical significance and testing standards of TMB,promoting more accurate interpretation of test results,and improving patient care.
- 关键词 Biomarkers tumor mutational burden tumor immunotherapy targeted panel sequencing whole-exome sequencing
- 分类号 R730.4 [医药卫生—肿瘤]
- 题名Human papillomavirus-associated diseases and cancers 认领 引用
- 2
- 作者 Lan Yang Jianbo Zhu Xiaoyue Song Yan Qi Xiaobin Cui Feng Li
- 机构 Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases,Shihezi University School of Medicine
- 出处 《Oncology and Translational Medicine》 CAS 2015年第3期109-114,共6页
- 基金 Supported by a grant from the National Natural Science Foundation of China(No.81260301)
- 摘要 Human papillomaviruses(HPVs) have been detected in cervical cancer cells and skin papilloma cells, which have a variety of types, including low-risk and high-risk types. HPV genome replication requires the host cell's DNA synthesis machinery, and HPVs encode proteins that maintain differentiated epithelial cells in a replication-competent state. HPV types are tissue-specific and generally produce different types of lesions, either benign or malignant. This review examines different HPV types and their associated diseases and presents therapeutic options for the treatment of HPV-positive diseases.
- 关键词 human papillomavirus （HPV） low-risk high-risk cancer
- 分类号 R730.2 [医药卫生—肿瘤]
